www.fdanews.com/articles/101146-crucell-dsm-ink-agreement-with-daiichi-sankyo
Crucell, DSM Ink Agreement With Daiichi Sankyo
November 16, 2007
DSM Biologics and Dutch biotechnology company Crucell have signed a PER.C6 license agreement with Japan’s Daiichi Sankyo for the PER.C6 cell line.
PER.C6 was developed for the manufacture of biopharmaceutical products, including monoclonal antibodies. The cell line will help Daiichi Sankyo in its early stage research to identify new antibodies and in the production of preclinical grade material, Crucell said.
Financial details were not disclosed.